Siderophore-antibiotic conjugate design: New drugs for bad bugs?

Molecules

Volumn 24, Issue 18, 2019, Pages

  Negash, Kokob H ^a   Norris, James K S ^a   Hodgkinson, James T ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Antibiotic; Antibiotic resistance; Siderophore; Siderophore antibiotic; Trojan horse

Indexed keywords

ANTIINFECTIVE AGENT; FERROUS ION; PEPTIDE; SIDEROMYCINS; SIDEROPHORE;

CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; HUMAN; SYNTHESIS;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FERROUS COMPOUNDS; HUMANS; PEPTIDES; SIDEROPHORES;

EID: 85072143254     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules24183314     Document Type: Review

References (67)

1. World Health Organization Antimicrobial resistance. Available online: https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/(accessed on 21 June 2019).
2. World Health Organization Antibiotic Resistance. Available online: https://www.who.int/news-room/factsheets/ detail/antibiotic-resistance (accessed on 21 June 2019).
3. Cunha, B.R.; Fonesca, L.P.; Calado, C.R.C. Antibiotic Discovery: Where Have We Come from, Where Do We Go? Antibiotics 2019, 8, 45, doi: 10.3390/antibiotics8020045.
4. Munita, J.M.; Arias, C.A. Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016, 4, doi: 10.1128/microbiolspec.VMBF-0016-2015.
5. Zgurskaya, H.I.; Löpez, C.A.; Gnanakaran, S. Permeability Barrier of Gram-Negative Cell Envelopes and Approaches to Bypass It. ACS Infect. Dis. 2015, 1, 512-522, doi: 10.1021/acsinfecdis.5b00097.
6. Hider. R.C.; Kong, X. Chemistry and biology of siderophores. Nat. Prod. Rep. 2010, 27, 637-657, doi: 10.1039/b906679a.
7. Golonka, R.; Yeoh, B.S.; Vijay-Kumar, M. The Iron Tug-of-War between Bacterial Siderophores and Innate Immunity. J. Innate Immun. 2019, 11, 249-262, doi: 10.1159/000494627.
8. Schalk, I.J.; Guillon, L. Fate of ferrisiderophores after import across bacterial outer membranes: Different iron release strategies are observed in the cytoplasm or periplasm depending on the siderophore pathways. Amino Acids 2013, 44, 1267-1277, doi:10.1007/s00726-013-1468-2.
9. Roosenberg, J.M. II; Lin, Y.M.; Lu, Y., Miller, M.J. Studies and Syntheses of Siderophores, Microbial Iron Chelators, and Analogs as Potential Drug Delivery Agents. Curr. Med. Chem. 2000, 7, 159-197, doi:10.2174/0929867003375353.
10. Zheng, T.; Nolan, E.M. Enterobactin-mediated delivery of β-lactam antibiotics enhances antibacterial activity against pathogenic Escherichia coli. J. Am. Chem. Soc. 2014, 136, 9677-9691, doi:10.1021/ja503911p.
11. Schalk, I.J. Siderophore-antibiotic conjugates: Exploiting iron uptake to deliver drugs into bacteria. Clin Microbiol. Infect. 2018, 24, 801-802, doi.org/10.1016/j.cmi.2018.03.037.
12. Zhanel, G.G.; Golden, A.R.; Zelenitsky, S.; Wiebe, K.; Lawrence, C.K.; Adam, H.J.; Idowu, T.; Domalaon, R.; Schweizer, F.; Zhanel, M.A.; et al. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 2019, 79, 271-289, doi: 10.1007/s40265-019-1055-2.
13. Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenemresistant Gram-negative Pathogens (CREDIBLE-CR) Available online: https://clinicaltrials.gov/ct2/show/record/NCT02714595 (accessed on 27 June 2019).
14. Ito, A.; Nishikawa, T.; Matsumoto, S.; Yoshizawa, H.; Sato. T.; Nakamura, R.; Tsuji, M.; Yamano, Y. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2016, 60, 7396-7401, doi: 10.1128/AAC.01405-16.
15. Braun, V.; Pramanik, A.; Gwinner, T.; Köberle, M.; Bohn, E. Sideromycins: Tools and antibiotics. Biometals 2009, 22, 3-13, doi: 10.1007/s10534-008-9199-7.
16. Gause, G.F. Recent studies on albomycin a new antibiotic. Brit. Med. J. 1955, 2, 1177-1179, doi:10.1136/bmj.2.4949.1177.
17. Benz, G.; Schröder, T.; Kurz, J.; Wünsche, C.; Karl, W. Steffens.; G., Pfitzner.; J.; Schmidt, D. Konstitution der Desferriform der Albomycine δ1, δ2, E. Angew. Chem. Int. 1982, 21, 1322-1335, doi.org/10.1002/anie.198213220.
18. Braun, V.; Braun, M. Active transport of iron and siderophore antibiotics. Curr Opin Microbiol. 2002, 5, 194-201, doi.org/10.1016/S1369-5274(02)00298-9.
19. Braun, V.; Braun, M. Iron transport and signaling in Escherichia coli. FEBS Lett. 2002, 529, 78-85, doi.org/10.1016/S0014-5793(02)03185-X.
20. Lin, Z.; Xu, X.; Zhao, S.; Yang, X.; Guo, J.; Zhang, Q.; Jing, C.; Chen, S.; He, Y. Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens. Nat. Commun. 2018, 9, 3445, doi: 10.1038/s41467-018-05821-1.
21. Zähner, H.; Diddens, H.; Keller-Schierlein, W.; Nägeli, H.U. Some experiments with semisynthetic sideromycins. Jpn J. Antibiot. 1977, 30, 201-206.
22. Dolence, E.K.; Lin, C.E.; Miller, M.J.; Payne, S.M. Synthesis and siderophore activity of albomycin-like peptides derived from N5-acetyl-N5-hydroxy-L-ornithine. J. Med. Chem. 1991, 34, 956-68.
23. Ohi, N.; Aoki, B.; Moro, K.; Kuroki, T.; Sugimura, N.; Noto, T.; Nehashi, T.; Matsumoto, M.; Okazaki, H.; Matsunaga, I. Semisynthetic β-lactam antibiotics I. Synthesis and antibacterial activity of new ureidopenicillin derivatives having catechol moieties. J. Antibiot. 1986, 39, 230-241.
24. Lin, Y.M.; Ghosh, M.; Miller, P.A.; Möllmann, U.; Miller, M.J. Synthetic sideromycins (skepticism and optimism): Selective generation of either broad or narrow spectrum Gram-negative antibiotics. Biometals 2019, 32, 425-451, doi:10.1007/s10534-019-00192-6.
25. Wencewicz, T.A.; Miller, M.J. Biscatecholate-monohydroxamate mixed ligand siderophorecarbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii. J. Med. Chem. 2013, 56, 4044-4052, doi:10.1021/jm400265k.
26. Neumann, W.; Sassone-Corsi, M.; Raffatellu, M.; Nolan, E.M. Esterase-Catalyzed Siderophore Hydrolysis Activates an Enterobactin-Ciprofloxacin Conjugate and Confers Targeted Antibacterial Activity. J. Am. Chem Soc. 2018, 140, 5193-5201, doi: 10.1021/jacs.8b01042.
27. Annamalai, R.; Jin, B.; Cao, Z.; Newton, S.M.; Klebba, P.E. Recognition of ferric catecholates by FepA. J. Bacteriol. 2004, 186, 3578-3589, doi: 10.1128/JB.186.11.3578-3589.2004.
28. Sheldon, J.R.; Heinrichs, D.E. Recent developments in understanding the iron acquisition strategies of gram positive pathogens. FEMS Microbiol Rev. 2015, 39, 592-630, doi: 10.1093/femsre/fuv009.
29. Wittmann, S.; Heinisch, L.; Scherlitz-Hofmann, I.; Stoiber, T.; Ankel-Fuchs, D.; Möllmann, U. Catecholates and mixed catecholate hydroxamates as artificial siderophores for mycobacteria. Biometals. 2004, 1, 53-64.
30. Tomaras, A.P.; Crandon, J.L.; McPherson, C.J.; Banevicius, M.A.; Finegan, S.M.; Irvine, R.L.; Brown, M.F.; O'Donnell, J.P.; Nicolau, D.P. Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013, 57, 4197-207, doi: 10.1128/AAC.00629-13.
31. Ji, C.; Miller, P.A.; Miller, M.J. Iron Transport-Mediated Drug Delivery: Practical Syntheses and In Vitro Antibacterial Studies of Tris-Catecholate Siderophore-Aminopenicillin Conjugates Reveals Selectively Potent Antipseudomonal Activity. J. Am. Chem Soc. 2012, 134, 9898-9901, doi.org/10.1021/ja303446w.
32. Fardeau, S.; Dassonville-Klimpt, A.; Audic, N.; Sasaki, A.; Pillon, M.; Baudrin, E.; Mullié, C.; Sonnet, P. Synthesis and antibacterial activity of catecholate-ciprofloxacin conjugates. Bioorg Med. Chem. 2014 22, 4049-4060, doi: 10.1016/j.bmc.2014.05.067.
33. Chairatana, P.; Zheng, T.; Nolan, E.M. Targeting virulence: Salmochelin modification tunes the antibacterial activity spectrum of β-lactams for pathogen-selective killing of Escherichia coli. Chem Sci. 2015, 6, 4458-4471, doi: 10.1039/c5sc00962f.
34. Ghosh, A.; Ghosh, M.; Niu, C.; Malouin, F.; Moellmann, U.; Miller, M.J. Iron transport-mediated drug delivery using mixed-ligand siderophore-beta-lactam conjugates. Chem Biol. 1996, 3, 1011-1019.
35. Kinzel, O.; Tappe, R.; Gerus, I.; Budzikiewicz, H. The synthesis and antibacterial activity of two pyoverdinampicillin conjugates, entering Pseudomonas aeruginosa via the pyoverdin-mediated iron uptake pathway. J. Antibiot. 1998, 51, 499-507, doi.org/10.7164/antibiotics.51.499.
36. Kinzel, O.; Budzikiewicz, H. Synthesis and biological evaluation of a pyoverdin-beta-lactam conjugate: A new type of arginine-specific cross-linking in aqueous solution. J. Pept Res. 1999, 53, 618-625, doi.org/10.1034/j.1399-3011.1999.00053.x.
37. Hennard, C.; Truong, Q.C.; Desnottes, J.F.; Paris, J.M.; Moreau, N.J.; Abdallah, M.A. Synthesis and activities of pyoverdin-quinolone adducts: A prospective approach to a specific Therapy against Pseudomonas aeruginosa. J. Med. Chem. 2001, 44, 2139-2151, doi.org/10.1021/jm990508g.
38. Wencewicz, T.A.; Long, T.E.; Möllmann, U.; Miller, M.J. Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus. Bioconjug Chem. 2013 24, 473-486, doi: 10.1021/bc300610f.
39. Milner, S.J.; Seve, A.; Snelling, A.M.; Thomas, G.H.; Kerr, K.G.; Routledge, A.; Duhme-Klair, A.K. Staphyloferrin A as siderophore-component in fluoroquinolone-based Trojan horse antibiotics. Org. Biomol. Chem. 2013, 11, 3461-3468, doi: 10.1039/c3ob40162f.
40. Paulen, A.; Gasser, V.; Hoegy, F.; Perraud, Q.; Pesset, B.; Schalk, I.J.; Mislin, G.L. Synthesis and antibiotic activity of oxazolidinone-catechol conjugates against Pseudomonas aeruginosa. Org. Biomol. Chem. 2015, 13, 11567-11579, doi: 10.1039/c5ob01859e.
41. Rivault, F.; Liébert, C.; Burger, A.; Hoegy, F.; Abdallah, M.A.; Schalk, I.J.; Mislin, G.L. Synthesis of pyochelin-norfloxacin conjugates. Bioorg. Med. Chem Lett. 2007, 17, 640-644. doi.org/10.1016/j.bmcl.2006.11.005.
42. Neumann, W.; Nolan, E.M. Evaluation of a reducible disulfide linker for siderophore-mediated delivery of antibiotics. J. Biol. Inorg. Chem. 2018, 23, 1025-1036, doi: 10.1007/s00775-018-1588-y.
43. Juárez-Hernández, R.E.; Miller, P.A.; Miller, M.J. Syntheses of Siderophore-Drug Conjugates Using a Convergent Thiol-Maleimide System. ACS Med. Chem. Lett. 2012, 3, 799-803, doi.org/10.1021/ml300150y.
44. Milner, S.J.; Snelling, A.M.; Kerr, K.G.; Abd-El-Aziz, A.; Thomas, G.H.; Hubbard, R.E.; Routledge, A.; Duhme-Klair, A.K. Probing linker design in citric acid-ciprofloxacin conjugates. Bioorg. Med. Chem. 2014, 22, 4499-4505, doi: 10.1016/j.bmc.2014.04.009.
45. Zheng, T.; Nolan, E.M. Evaluation of (acyloxy)alkyl ester linkers for antibiotic release from siderophoreantibiotic conjugates. Bioorg. Med. Chem. Lett. 2015, 25, 4987-4991, doi.org/10.1016/j.bmcl.2015.02.034.
46. Liu, R.; Miller, P.A.; Vakulenko, S.B.; Stewart, N.K.; Boggess, W.C.; Miller, M.J. A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria to Commit Suicide with a Gram-Positive Antibiotic. J. Med. Chem. 2018, 61, 3845-3854, doi: 10.1021/acs.jmedchem.8b00218.
47. Ji, C.; Miller, M.J. Chemical syntheses and in vitro antibacterial activity of two desferrioxamine Bciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers. Bioorg Med. Chem. 2012, 20, 3828-3836, doi: 10.1016/j.bmc.2012.04.034.
48. Brochu, A.; Brochu, N.; Nicas, T.; Parr, T.R. Jr.; Minnick, A.A. J. Dolence, E.K.; McKee, J.A.; Miller, M.J.; Lavoie, M.C.; Malouin, F. Modes of action and inhibitory activities of new siderophore-beta-lactam conjugates that use specific iron uptake pathways for entry into bacteria. Antimicrob Agents Chemother. 1992, 36, 2166-2175, doi: 10.1128/AAC.36.10.2166.
49. Wencewicz, T.A.; Möllmann, U.; Long, T.E.; Miller, M.J.; Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin "Trojan Horse" antibiotics and synthetic desferridanoxamine-antibiotic conjugates. Biometals 2009, 22, 633-648, doi: 10.1007/s10534-009-9218-3.
50. Schalk, I.J.; Mislin, G.L.A. Bacterial Iron Uptake Pathways: Gates for the Import of Bactericide Compounds. J. Med. Chem. 2017, 60, 4573-4576, doi: 10.1021/acs.jmedchem.7b00554.
51. Noël, S1.; Gasser, V.; Pesset, B.; Hoegy, F.; Rognan, D.; Schalk, I.J.; Mislin, G.L. Synthesis and biological properties of conjugates between fluoroquinolones and a N3'-functionalized pyochelin. Org. Biomol Chem. 2011, 9, 8288-8300, doi: 10.1039/c1ob06250f.
52. Ji, C.; Miller, M.J. Siderophore-fluoroquinolone conjugates containing potential reduction-triggered linkers for drug release: Synthesis and antibacterial activity. Biometals 2015, 28, 541-551, doi: 10.1007/s10534-015-9830-3.
53. Klahn, P. &M. Brönstrup. Bifunctional antimicrobial conjugates and hybrid antimicrobials. Nat. Prod. Rep. 2017, 34, 832-885, doi: 10.1039/c7np00006e.
54. Ji, C.; Juárez-Hernández, R.E.; Miller, M.J. Exploiting bacterial iron acquisition: Siderophore conjugates. Future med. chem. 2012, 4, 297-313, doi.org/10.4155/fmc.11.191.
55. Benedetto Tiz, D.; Kikelj, D.; Zidar, N.; Overcoming problems of poor drug penetration into bacteria: Challenges and strategies for medicinal chemists. Expert opin. drug del. 2018, 13, 497-507, doi: org/10.1080/17460441.2018.1455660.
56. Ghosh, M.; Miller, M.J. Synthesis and in vitro antibacterial activity of spermidine-based mixed catecholand hydroxamate-containing siderophore-vancomycin conjugates. Bioorg. Med. Chem. 1996, 4, 43-48, doi.org/10.1016/0968-0896(95)00161-1.
57. Ghosh, M.; Miller, M.J.; Design, Synthesis, and Biological Evaluation of Isocyanurate-based Antifungal and Macrolide Antibiotic Conjugates: Iron Transport-mediated Drug Delivery. Bioorg. Med. Chem. 1995, 3, 1519-1525, doi.org/10.1016/0968-0896(95)00134-3.
58. Lu, Y.; Miller, M.J. Syntheses and studies of multiwarhead siderophore-5-fluorouridine conjugates. Bioorg Med. Chem. 1999, 7, 3025-3038, doi.org/10.1016/S0968-0896(99)00248-5.
59. Miller, M.J.; Walz, A.J.; Zhu, H.; Wu, C.; Moraski, G.; Möllmann, U.; Tristani, E.M.; Crumbliss, A.L.; Ferdig, M.T.; Checkley, L.; et al. Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. J. Am. Chem Soc. 2011, 133, 2076-2079, doi: 10.1021/ja109665t.
60. Tarapdar, A.; Norris, J.K.S.; Sampson, O.; Mukamolova, G.; Hodgkinson, J.T. The design and synthesis of an antibacterial phenothiazine-siderophore conjugate. Beilstein J. Org. Chem. 2018, 14, 2646-2650, doi:10.3762/bjoc.14.242.
61. Warman, A.J.; Rito, T.S.; Fisher, N.E.; Moss, D.M.; Berry, N.G.; O'Neill, P.M.; Ward, S.A.; Biagini, G.A. Antitubercular pharmacodynamics of phenothiazines. J. Antimicrob Chemother. 2013, 68, 869-80, doi:10.1093/jac/dks483.
62. Deris, Z.Z.; Akter, J.; Sivanesan, S.; Roberts, K.D.; Thompson, P.E.; Nation, R.L.; Li, J.; Velkov, T. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADHquinone oxidoreductase activity. J. Antibiot 2014, 67, 147-151, doi: 10.1038/ja.2013.111.
63. Alt, S.; Burkard, N.; Kulik, A.; Grond, S.; Heide, L. An artificial pathway to 3,4-dihydroxybenzoic acid allows generation of new aminocoumarin antibiotic recognized by catechol transporters of E. coli. Chem Biol. 2011, 18, 304-313, doi: 10.1016/j.chembiol.2010.12.016.
64. Kali, A. Teixobactin: A novel antibiotic in treatment of gram positive bacterial infections. J. Clin Diagn Res. 2015, 9, DL01, doi: 10.7860/JCDR/2015/13033.5720.
65. Ghosh, M.; Miller, P.A.; Möllmann, U.; Claypool, W.D.; Schroeder, V.A.; Wolter, W.R.; Suckow, M.; Yu, H.; Li, S.; Huang, W.; et al. Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. J. Med. Chem. 2017, 60, 4577-4583, doi: 10.1021/acs.jmedchem.7b00102.
66. Paulen, A.; Hoegy, F.; Roche, B.; Schalk, I.J.; Mislin, G.L.A. Synthesis of conjugates between oxazolidinone antibiotics and a pyochelin analogue. Bioorg Med. Chem Lett. 2017, 27, 4867-4870, doi: 10.1016/j.bmcl.2017.09.039.
67. Blaskovich, M.A.T.; Zuegg, J.; Elliott, A.G.; Cooper, M.A. Helping Chemists Discover New Antibiotics. ACS Infect. Dis. 2015, 1, 285-287, doi: 10.1021/acsinfecdis.5b00044.